TAK-280

N/A

Report date: 2026/03/19 17:01:32

Base Information

Drug NameTAK-280

Drug Alias NameMVC-280TAK-280

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 stimulantsAnti-CD276

TargetsT cell surface glycoprotein CD3CD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMaverick Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMaverick Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A